Aarkstore.com announces, a new market research report is available in its vast collection The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways http://www.aarkstore.com/reports/The-Future-of-Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways-107105.html Summary: The leading business intelligence provider, has released its latest research “The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways”. The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are provided in the report. The report discusses the latest developments in the regulatory landscape and the evolving biosimilars approval pathways in Europe, the US and Japan. In-depth analysis into the individual segments of biosimilars market, their market forecasts and potential are also provided. The study analyzes the competitive landscape including benchmarking of the leading companies in the biosimilars market. Scope The scope of this report includes: Analysis on the regulations for biosimilars market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan Market forecasts and potential for the biosimilars market from 2008 to 2015. The key biologics classes included are human growth hormones, granulocyte colony stimulating factors, insulins, interferons and erythropoietins Market characterization data for biosimilars including market size, market share and market potential Key drivers and restraints that have a significant impact on the market Competitive landscape of global biosimilars market including benchmarking of the leading companies. The key companies discussed in this report are Teva, Sandoz, Hospira Inc, STADA Arzneimittel AG, Ratiopharm, Dr.Reddy’s Laboratories and Biocon Ltd Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global biosimilars market Reasons to Buy The report will enable business development and marketing executives strategizing their product launches to Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the US, Europe and Japan Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps Develop key strategic initiatives by studying the key strategies of top competitors Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety Table of Contents : 1 Drug Discovery In India and China – Executive Summary 1.1 Rising Financial and Regulatory Pressures on Western Pharma will Continue to Drive the Drug Discovery

1. Aarkstore.com announces, a new market research report is available in its vast collection
The Future of Biosimilars - Market Forecasts to 2015,
Opportunity Analysis and Regulatory Pathways
http://www.aarkstore.com/reports/The-Future-of-Biosimilars-Market-Forecasts-to-
2015-Opportunity-Analysis-and-Regulatory-Pathways-107105.html
Summary:
The leading business intelligence provider, has released its latest research “The
Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and
Regulatory Pathways”. The report provides insights on the biosimilars market
revenues and growth until 2015. Further, the distribution of revenues across key
geographies such as the US, the top five countries in Europe and Japan are
provided in the report. The report discusses the latest developments in the
regulatory landscape and the evolving biosimilars approval pathways in Europe, the
US and Japan. In-depth analysis into the individual segments of biosimilars market,
their market forecasts and potential are also provided. The study analyzes the
competitive landscape including benchmarking of the leading companies in the
biosimilars market.
Scope
The scope of this report includes:
Analysis on the regulations for biosimilars market in the leading geographies of the
world – the US, the UK, Germany, France, Italy, Spain, and Japan
Market forecasts and potential for the biosimilars market from 2008 to 2015. The
key biologics classes included are human growth hormones, granulocyte colony
stimulating factors, insulins, interferons and erythropoietins
Market characterization data for biosimilars including market size, market share and
market potential
Key drivers and restraints that have a significant impact on the market

2. Competitive landscape of global biosimilars market including benchmarking of the
leading companies. The key companies discussed in this report are Teva, Sandoz,
Hospira Inc, STADA Arzneimittel AG, Ratiopharm, Dr.Reddy’s Laboratories and
Biocon Ltd
Key M&A activities, licensing agreements, that have taken place between 2008 and
2009 in the global biosimilars market
Reasons to Buy
The report will enable business development and marketing executives strategizing
their product launches to
Build effective strategies to launch pipeline products by identifying the latest
regulatory developments in the US, Europe and Japan
Develop market-entry and market expansion strategies by identifying the
geographic markets poised for strong growth
Exploit in-licensing and out-licensing opportunities by identifying products that
could fill their portfolio gaps
Develop key strategic initiatives by studying the key strategies of top competitors
Reinforce R&D pipelines by identifying licensing strategies for acquiring new
delivery mechanisms that have more efficiency and better safety
Table of Contents :
1 Drug Discovery In India and China – Executive Summary
1.1 Rising Financial and Regulatory Pressures on Western Pharma will Continue to
Drive the Drug Discovery Research Market Growth in India and China
1.2 Inflammatory Diseases, Metabolic Disorders and Oncology are the Three Major
Therapeutic Areas of Drug Discovery Research in India and China
1.3 Deals Landscape is Equally Driven by Mid-Size Pharma and Big Pharma with
Oncology and Metabolic Disorders as Key Therapy Area of Focus

3. 1.4 Funding Problems and Talent Shortage Will Be the Two Biggest Challenges in
Future for the Drug Discovery Players in India and China
For More details Plz do contact :
Aarkstore Enterprise
Phone:08149852585
Email: enquiry@aarkstore.com
URL:www.aarkstore.com
Our Website :www.aarkstore.com
Facebook: http://www.facebook.com/aarkstore
Linkedin: http://in.linkedin.com/in/aarkstore